Decreased internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib

IEE Proceedings: Systems Biology

Volumn 153, Issue 6, 2006, Pages 457-466

  Hendriks, B S ^a   Griffiths, G J ^a   Benson, R ^a   Kenyon, D ^a   Lazzara, M ^b   Swinton, J ^a   Beck, S ^a   Hickinson, M ^a   Beusmans, J M ^a   Lauffenburger, D ^b   de Graaf, D ^a  

^a ASTRAZENECA   (United Kingdom)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

A8710; A8715; A8725D; A8770G; Cancer; Cell survival; Cellular transport; Decreased ErbB1 mutant internalisation; Drugs; Enzymes; ErbB1 signalling; ErbB1 trafficking; Gefitinib responsive tumours; Internalisation deficient ErbB1 receptors; Lung; Lung cancer cell lines; Molecular biophysics; Nonsmall cell lung cancer; Oncogenesis; Physiological models; Tumours; Upregulated AKT signalling

Indexed keywords

CELL CULTURE; COMPUTATIONAL METHODS; MATHEMATICAL MODELS; ONCOLOGY; PULMONARY DISEASES; TUMORS;

GEFITINIB SENSITIVITY; INTERNALISATION RATES; LUNG CANCER; ONCOGENESIS;

CYTOLOGY;

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MUTANT PROTEIN; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; LUNG CANCER; MATHEMATICAL MODEL; PHENOTYPE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTER SIMULATION; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33750816028     PISSN: 17412471     EISSN: None     Source Type: Journal    
DOI: 10.1049/ip-syb:20050108     Document Type: Article

References (53)

1. Yarden, Y., and Sliwkowski, M.X.: 'Untangling the ErbB signalling network', Nat. Rev. Mol. Cell. Biol., 2001, 2, p. 127-137
2. Wakeling, A.E., Guy, S.P., Woodburn, J.R., Ashton, S.E., Curry, B.J., Barker, A.J.,Aand Gibson, K.H.: 'ZD 1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy', Cancer Res., 2002, 62, p. 5749-5754
3. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib', N. Engl. J. Med., 2004, 350, p. 2129-2139
4. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M.: 'EGFR mutatiCns in lung cancer: correlation with clinical response to gefitinib therapy', Science, 2004, 304, p. 1497-1500 0036-8075
5. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., and Varmus, H.: 'EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib', Proc. Natl. Acad. Sci. USA, 2004, 101, p. 13306-13311 0027-8424
6. Yeh, K.H., Yeh, S.H., Wan, J.P., Shen, Y.C., and Cheng, A.L.: 'Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung', Anticancer Drugs, 2005, 16, p. 739-742
7. Zhang, X.T., Li, L.Y., Mu, X.L., Cui, Q.C., Chang, X.Y., Song, W., Wang, S.L., Wang, M.Z., Zhong, W., and Zhang, L.: 'The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer', Ann. Oncol., 2005, 16, p. 1334-1342
8. Mu, X.L., Li, L.Y., Zhang, X.T., Wang, M.Z., Feng, R.E., Cui, Q.C., Zhou, H.S., and Guo, B.Q.: 'Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer', Clin. Cancer. Res., 2005, 11, p. 4289-4294
9. Chou, T.Y., Chiu, C.H., Li, L.H., Hsiao, C.Y., Tzen, C.Y., Chang, K.T., Chen, Y.M., Perng, R.P., Tsai, S.F., and Tsai, C.M.: 'Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer', Clin. Cancer. Res., 2005, 11, p. 3750-3757
10. Lynch, T.J.: Et al. 'Correlation of molecular markers including mutations with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials', J. Clin. Oncol. Suppl., 2005, 23, (Abstract 7006)
11. Bell, D.W.: Et al. 'Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials', J. Clin. Oncol., in press
12. Pao, W., and Miller, V.A.: 'Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions', J. Clin. Oncol., 2005, 23, p. 2556-2568
13. Janne, P.A., Engelman, J.A., and Johnson, B.E.: 'Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology', J. Clin. Oncol., 2005, 23, p. 3227-3234
14. Tsao, M.S., Sakurada, A., Cutz, J.C., Zhu, C.Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., Marrano, P., da Cunha Santos, G., Lagarde, A., Richardson, F., Seymour, L., Whitehead, M., Ding, K., Pater, J., and Shepherd, F.A.: 'Erlotinib in lung cancer-molecular and clinical predictors of outcome', N. Engl. J. Med., 2005, 353, p. 133-144
15. Fabian, M.A., Biggs, W.H., Treiber, D.K., Atteridge, C.E., Azimioara, M.D., Benedetti, M.G., Carter, T.A., Ciceri, P., Edeen, P.T., Floyd, M., Ford, J.M., Galvin, M., Gerlach, J.L., Grotzfeld, R.M., Herrgard, S., Insko, D.E., Insko, M.A., Lai, A.G., Lelias, J.M., Mehta, S.A., Milanov, Z.V., Velasco, A.M., Wodicka, L.M., Patel, H.K., Zarrinkar, P.P., and Lockhart, D.J.: 'A small molecule-kinase interaction map for clinical kinase inhibitor', Nat. Biotechnol., 2005, 23, p. 329-336
16. Sordella, R., Bell, D.W., Haber, D.A., and Settleman, J.: 'Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways', Science, 2004, 305, p. 1163-1167 0036-8075
17. Lund, K.A., Opresko, L.K., Starbuck, C., Walsh, B.J., and Wiley, H.S.: 'Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization', J. Biol. Chem., 1990, 265, p. 15713-15723
18. Burke, P.M., and Wiley, H.S.: 'Human mammary epithelial cells rapidly exchange empty EGFR between surface and intracellular pools', J. Cell. Physiol., 1999, 180, p. 448-460
19. Kovacina, K.S., Park, G.Y., Bae, S.S., Guzzetta, A.W., Schaefer, E., Birnbaum, M.J., and Roth, R.A.: 'Identification of a proline-rich Akt substrate as a 14-3-3 binding partner', J. Biol. Chem., 2003, 278, p. 10189-10194
20. Hendriks, B.S., Opresko, L.K., Wiley, H.S., and Lauffenburger, D.: 'Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects', Cancer Res., 2003, 63, p. 1130-1137
21. Hendriks, B.S., Opresko, L.K., Wiley, H.S., and Lauffenburger, D.: 'Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: Distribution of homo- and heterodimers depends on relative HER2 levels', J. Biol. Chem., 2003, 278, p. 23343-23351
22. Hendriks, B.S., Cook, J., Burke, J.M., Beusmans, J., Lauffenburger, D., and de Graaf, D.: 'Computational modeling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity', IEE Proc. Syst. Biol., 2006, 153, p. 22-33 10.1049/ip-syb:20050057
23. Sorkin, A., and Carpenter, G.: 'Dimerization of internalized epidermal growth factor receptors', J. Biol. Chem., 1991, 266, p. 23453-23460
24. French, A.R., Tadaki, D.K., Niyogi, S.K., and Lauffenburger, D.A.: 'Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction', J. Biol. Chem., 1995, 270, p. 4334-4340
25. Lauffenburger, D., and Linderman, J.J.: 'Receptors', (Oxford University Press, New York 1993)
26. Offterdinger, M., Georget, V., Girod, A., and Bastiaens, P.I.: 'Imaging phosphorylation dynamics of the EGF receptor', J. Biol. Chem., 2004, 279, (35), p. 36972-36981
27. Asthagiri, A.R., and Lauffenburger, D.A.: 'A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (MAPK) pathway model', Biotechnol. Prog., 2001, 17, p. 227-239
28. Kholodenko, B.N., Demin, O.V., Moehren, G., and Hoek, J.B.: 'Quantification of short term signaling by the epidermal growth factor receptor', J. Biol. Chem., 1999, 274, p. 30169-30181
29. Haugh, J.M.: 'Localization of receptor-mediated signal transduction pathways: The inside story', Mol. Intervent., 2002, 2, p. 292-307
30. Haugh, J.M., Huang, A.C., Wiley, H.S., Wells, A., and Lauffenburger, D.A.: 'Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts', J. Biol. Chem., 1999, 274, p. 34350-34360
31. Hatakeyama, M., Kimura, S., Naka, T., Kawasaki, T., Yumoto, N., Ichikawa, M., Kim, J.H., Saito, K., Saeki, M., Shirouzu, M., Yokoyama, S., and Konagaya, A.: 'A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling', Biochem. J., 2003, 373, p. 451-463
32. Rodrigues, G.A., Falasca, M., Zhang, Z., Ong, S.H., and Schlessinger, J.: 'A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling', Mol. Cell. Biol., 2000, 20, p. 1448-1459
33. Schoeberl, B., Eichler-Jonsson, C., Gilles, E.D., and Muller, G.: 'Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors', Nat. Biotechnol., 2002, 20, p. 370-375
34. Haugh, J.M., and Meyer, T.: 'Active EGF receptors have limited access to PtdIns(4,5)P(2) in endosomes: Implications for phospholipase C and PI 3-kinase signaling', J. Cell. Sci., 2002, 115, p. 303-310
35. Arao, T., Fukumoto, H., Takeda, M., Tamura, T., Saijo, N., and Nishio, K.: 'Small in-frame deletion in the epidermal growth factor receptor as a target for ZD 6474', Cancer Res., 2004, 64, p. 9101-9104
36. Hickinson, M., Beck, S., McCormack, R., Smith, P.D., Holloway, B., and Speake, G.: 'Increasing our molecular understanding of the clinical response of gefitinib (IRESSA) using pre-clinical in vitro models of lung cancer', Mol. Cancer. Ther., in press
37. Sorkina, T., Huang, F., Beguinot, L., and Sorkin, A.: 'Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor', J. Biol. Chem., 2002, 277, p. 27433-27441
38. Wiley, H.S., Herbst, J.J., Walsh, B.J., Lauffenburger, D.A., Rosenfeld, M.G., and Gill, G.N.: 'The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor', J. Biol. Chem., 1991, 266, p. 11083-11094
39. Schmidt, M.H., Furnari, F.B., Cavenee, W.K., and Bogler, O.: 'Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization', Proc. Natl. Acad. Sci. USA, 2003, 100, p. 6505-6510 0027-8424
40. Wiley, H.S., and Cunningham, D.D.: 'The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis', J. Biol. Chem., 1982, 257, p. 4222-4229
41. Cappuzzo, F., Magrini, E., Ceresoli, G.L., Bartolini, S., Rossi, E., Ludovini, V., Gregorc, V., Ligorio, C., Cancellieri, A., Damiani, S., Spreafico, A., Paties, C.T., Lombardo, L., Calandri, C., Bellezza, G., Tonato, M., and Crino, L.: 'Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer', J. Natl. Cancer. Inst., 2004, 96, p. 1133-1141
42. Marmor, M.D., and Yarden, Y.: 'Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases', Oncogene, 2004, 23, p. 2057-2070
43. Shimamura, T., Lowell, A.M., Engelman, J.A., and Shapiro, G.I.: 'Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins', Cancer Res., 2005, 65, p. 6401-6408
44. Vieira, A.V., Lamaze, C., and Schmid, S.L.: 'Control of EGF receptor signaling by clathrin-mediated endocytosis', Science, 1996, 274, p. 2086-2089 0036-8075
45. Wells, A., Welsh, J.B., Lazar, C.S., Wiley, H.S., Gill, G.N., and Rosenfeld, M.G.: 'Ligand-induced transformation by a noninternalizing epidermal growth factor receptor', Science, 1990, 247, p. 962-964 0036-8075
46. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L.: 'Cuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene', Science, 1987, 235, p. 177-182 0036-8075
47. Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F., and Arteaga, C.L.: 'Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo', Cancer Res., 2001, 61, p. 8887-8895
48. Moasser, M.M., Basso, A., Averbuch, S.D., and Rosen, N.: 'The tyrosine kinase inhibitor ZD 1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells', Cancer Res., 2001, 61, p. 7184-7188
49. Kwak, E.L., Sordella, R., Bell, D.W., Godin-Heymann, N., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Driscoll, D.R., Fidias, P., Lynch, T.J., Rabindran, S.K., McGinnis, J.P., Wissner, A., Sharma, S.V., Isselbacher, K.J., Settleman, J., and Haber, D.A.: 'Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib', Proc. Natl. Acad. Sci. USA, 2005, 102, p. 7665-7670 0027-8424
50. Amann, J., Kalyankrishna, S., Massion, P.P., Ohm, J.E., Girard, L., Shigematsu, H., Peyton, M., Juroske, D., Huang, Y., Stuart Salmon, J., Kim, Y.H., Pollack, J.R., Yanagisawa, K., Gazdar, A., Minna, J.D., Kurie, J.M., and Carbone, D.P.: 'Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer', Cancer Res., 2005, 65, p. 226-235
51. Engelman, J.A., Janne, P.A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B.E., and Cantley, L.C.: 'ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines', Proc. Natl. Acad. Sci. USA, 2005, 102, p. 3788-3793 0027-8424
52. Waterman, H., Sabanai, I., Geiger, B., and Yarden, Y.: 'Alternative intracellular routing of ErbB receptors may determine signaling potency', J. Biol. Chem., 1998, 273, p. 13819-13827
53. Shea, L.D., Omann, G.M., and Linderman, J.J.: 'Calculation of diffusion-limited kinetics for the reactions in collision coupling and receptor cross-linking', Biophys. J., 1997, 73, p. 2949-2959 0006-3495